Ploidy and clinical characteristics of childhood acute myeloid leukemia: A NOPHO-AML study

被引:25
|
作者
Sandahl, Julie Damgaard [1 ]
Kjeldsen, Eigil [2 ]
Abrahamsson, Jonas [3 ]
Ha, Shau-Yin [4 ,5 ]
Heldrup, Jesper [6 ]
Jahnukainen, Kirsi [7 ,8 ]
Jonsson, Olafur G. [9 ]
Lausen, Birgitte [10 ]
Palle, Josefine [11 ]
Zeller, Bernward [12 ]
Forestier, Erik [13 ]
Hasle, Henrik [1 ]
机构
[1] Aarhus Univ Hosp, Dept Pediat, DK-8200 Aarhus N, Denmark
[2] Aarhus Univ Hosp, Dept Hematol, Canc Cytogenet Lab, DK-8200 Aarhus N, Denmark
[3] Queen Silvia Childrens Hosp, Inst Clin Sci, Dept Pediat, Gothenburg, Sweden
[4] Queen Mary Hosp, Dept Paediat, Hong Kong, Hong Kong, Peoples R China
[5] HKPHOSG, Hong Kong, Hong Kong, Peoples R China
[6] Univ Lund Hosp, Dept Pediat, S-22185 Lund, Sweden
[7] Univ Helsinki, Cent Hosp, Childrens Hosp, Helsinki, Finland
[8] Univ Helsinki, Helsinki, Finland
[9] Landspitalinn, Dept Pediat, Reykjavik, Iceland
[10] Univ Copenhagen, Rigshosp, Dept Pediat & Adolescent Med, DK-2100 Copenhagen, Denmark
[11] Uppsala Univ, Dept Womans & Childrens Hlth, Uppsala, Sweden
[12] Oslo Univ Hosp, Dept Pediat Med, Oslo, Norway
[13] Umea Univ, Dept Med Biosci, Umea, Sweden
来源
GENES CHROMOSOMES & CANCER | 2014年 / 53卷 / 08期
关键词
ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MEGAKARYOBLASTIC LEUKEMIA; CYTOGENETIQUE-HEMATOLOGIQUE GFCH; PEDIATRIC-PATIENTS; ONCOLOGY-GROUP; MODAL NUMBER; CHILDREN; CHROMOSOMES; HYPERDIPLOIDY; ADOLESCENTS;
D O I
10.1002/gcc.22177
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We report the first large series (n=596) of pediatric acute myeloid leukemia (AML) focusing on modal numbers (MN) from the population-based NOPHO-AML trials. Abnormal karyotypes were present in 452 cases (76%) and numerical aberrations were present in 40% (n=237) of all pediatric AML. Among patients with an abnormal karyotype, the MN 46 was most common (n=251; 56%) of which 36 (8%) were pseudodiploid with numerical aberrations, followed by MN 47 (n=80; 18%) and MN 43-45 (n=48; 8%). No cases had MN less than 43. Hyperdiploid AML with MN 48-65 comprised 11% of all cases and was associated with early onset (median age 2 years), female sex (57%), and a dominance of acute megakaryoblastic leukemia (AMKL) (29%). Hypodiploidy constituted 8% of all AML and was associated with older age (median age 9 years), male predominance (60%), FAB M2 (56%), and t(8;21)(q22;q22) (56%) with loss of sex chromosomes. Inferior outcome was observed for hypodiploid cases (5-year event-free survival 40% and 5-year overall survival 40%) but did not reach statistical significance. Chromosomes were gained in a nonrandom pattern, where chromosomes 8, 21, 19, and 6 were the most commonly gained. In conclusion, based on MNs, two cytogenetic subgroups with characteristic clinical features are described; hypodiploidy found in 8% and associated with high median age, male sex, t(8;21)(q22;q22), and FAB M2 and possibly associated with inferior outcome (P=0.13), and hyperdiploidy with MN 48-65 in 11% associated with early onset, female sex, and AMKL. (c) 2014 Wiley Periodicals, Inc.
引用
收藏
页码:667 / 675
页数:9
相关论文
共 50 条
  • [41] Characteristics and outcomes of acute myeloid leukemia (AML) with extramedullary disease (EMD).
    Yalniz, Fevzi Firat
    Cortes, Jorge E.
    Borthakur, Gautam
    Garcia-Manero, Guillermo
    Kadia, Tapan M.
    Konopleva, Marina
    Dinardo, Courtney Denton
    Daver, Naval Guastad
    Wierda, William G.
    Verstovsek, Srdan
    Pemmaraju, Naveen
    Estrov, Zeev
    Ravandi, Farhad
    Kantarjian, Hagop M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [42] Prognostic factors in childhood acute myeloid leukemia (AML): Experience on pediatric oncology group (POG) 8821 AML study.
    Ravindranath, Y
    Chang, M
    Camitta, B
    Steuber, CP
    Carroll, A
    Gresik, MV
    Raimondi, S
    Weinstein, H
    BLOOD, 1995, 86 (10) : 2385 - 2385
  • [43] Low efficacy of methotrexate in childhood acute myeloid leukemia (AML): Single-agent therapeutic window study in relapsed AML
    Kaspers, G. J. L.
    Reinhardt, D.
    Fleischhack, G.
    Armendariz, H.
    Stark, B.
    Zwaan, C. M.
    Zimmermann, M.
    Creutzig, U.
    PEDIATRIC BLOOD & CANCER, 2006, 47 (05) : 539 - 542
  • [44] Gemtuzumab Ozogamicin as Post-Consolidation Therapy Does Not Prevent Relapse In Children with AML. Results of the NOPHO-AML 2094 Study
    Hasle, Henrik
    Abrahamsson, Jonas
    Forestier, Erik
    Ha, Shau-Yin
    Heldrup, Jesper
    Jahnukainen, Kirsi
    Jonsson, Olafur G.
    Lausen, Birgitte
    Palle, Josefine
    Zeller, Bernward
    BLOOD, 2011, 118 (21) : 667 - 667
  • [45] Clinical and cytogenetic responses to amonafide in secondary acute myeloid leukemia (AML).
    Allen, S. L.
    Kolitz, J. E.
    Lundberg, A. S.
    Capizzi, R. L.
    Budman, D. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 357S - 357S
  • [46] Disparities in pediatric acute myeloid leukemia (AML) clinical trial enrollment
    Winestone, Lena E.
    Getz, Kelly D.
    Rao, Pooja
    Li, Yimei
    Hall, Matt
    Huang, Yuan-Shung V.
    Seif, Alix E.
    Fisher, Brian T.
    Aplenc, Richard
    LEUKEMIA & LYMPHOMA, 2019, 60 (09) : 2190 - 2198
  • [47] Gingival hyperplasia as first clinical sign of acute myeloid leukemia (AML)
    Ghidini, Giulia
    Meleti, Marco
    Vescovi, Paolo
    Manfredi, Maddalena
    DENTAL CADMOS, 2023, 91 (08) : 676 - 679
  • [48] Haematopoietic Cell Transplant (HCT) in Pediatric Acute Myeloid Leukemia (AML) after Similar Upfront Therapy with AML-Nopho; a Comparison of Conditioning Regimens
    Versluys, Birgitta
    Mellgren, Karin
    Pronk, Cornelis Jan
    Bordon, Victoria
    Lankester, Arjan
    Kollen, Wouter
    Boelens, Jaap-Jan
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (03) : S106 - S107
  • [49] EPIDEMIOLOGY AND CLINICAL CHARACTERISTICS OF BACTEREMIA IN ACUTE MYELOID LEUKEMIA (AML): EXPERIENCE IN A TERTIARY REFERRAL CENTRE IN PORTUGAL
    Koehler, M.
    Parreira, J.
    Nunes, A.
    HAEMATOLOGICA, 2014, 99 : 746 - 746
  • [50] Excellent outcome of risk stratified treatment for childhood acute myeloid leukemia-AML99 trial - For the Japanese Childhood AML Cooperative Study Group
    Tsukimoto, I
    Tawa, A
    Hanada, R
    Tabuchi, K
    Kigasawa, H
    Tsuchiya, S
    Tsuchida, M
    Yabe, H
    Nakayama, H
    Kudo, K
    Kobayashi, R
    Hamamoto, K
    Imaizumi, M
    Morimoto, A
    Horibe, K
    BLOOD, 2005, 106 (11) : 261A - 261A